| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate |
2011-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013523722-A |
| titleOfInvention |
Insulin drug conjugates using immunoglobulin fragments |
| abstract |
The present invention relates to an insulin conjugate having improved in vivo persistence and stability, which is produced by covalently linking insulin to an immunoglobulin Fc region with a non-peptide polymer, and a sustained-release preparation comprising the same And a method for manufacturing the same. The present invention provides a method of treating an individual having an insulin disorder such as diabetes. Since the insulin conjugate of the present invention maintains the in vivo activity of the peptide at a relatively high level and the blood half-life is greatly increased, the compliance with insulin during insulin treatment can be remarkably improved. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020513019-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7333249-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017505141-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018508504-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016529227-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016525099-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019163258-A |
| priorityDate |
2010-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |